Representational Veracity in Data Science Health Research: A Companion Viewpoint on Targets, Proxies, Labels, and Descriptors (Preprint)
Authors:
- Clement AdebamowoCAClement Adebamowo
- Sally N AdebamowoSASally N Adebamowo
- Adeola AkintolaAAAdeola Akintola
- Peter IkhanePIPeter Ikhane
- Simisola AkintolaSASimisola Akintola
- Temidayo OgundiranTOTemidayo Ogundiran
- Ayodele JegedeAJAyodele Jegede
- Olusegun AdeyemoOAOlusegun Adeyemo
- Shawneequa CallierSCShawneequa Callier
- Muhammad K Imam-ThamimMIMuhammad K Imam-Thamim
- Ibrahim UthmanIUIbrahim Uthman
Preprint
- 26 May 2026
- preprint
- Published by JMIR Publications Inc. in JMIR Preprints
Abstract
UNSTRUCTURED Prevailing ethical oversight of data science health research concentrates on privacy, consent, bias, and fairness. These concerns are necessary but insufficient, because they presuppose that the targets, proxies, labels, classifications, ontologies, and population descriptors already truthfully represent the populations and phenomena they claim to describe. That prior question is often left unexamined. In this Viewpoint, we introduce representational veracity (RV) as a companion concept to the Continuity Trap (CT) framework, grounded in a persistence-based account of representational adequacy developed in the parent framework manuscript. The Continuity Trap names the governance error in which a salient signal of continuity in one domain - technical, administrative, or infrastructural - is treated as sufficient evidence that ethical continuity has been preserved across all domains. In contrast, RV asks whether stored data continue to accurately and responsibly represent the persons, communities, and phenomena from which they were derived — at the point of use, not merely the point of collection. We draw on scholarship in quantification, classification, measurement, critical data studies, algorithmic fairness, and health artificial-intelligence (AI) governance to show that a model may be accurate, reproducible, and formally fair while resting on a representation that is too thin, unstable, or normatively misdirected for the proposed use. Our analysis proceeds through the four-domain representational-veracity architecture (material provenance, informational descriptors, normative authorization, relational community), examines four recurrent failure modes (proxy substitution, category misassignment, label-generation error, descriptor sedimentation), and applies these to a polygenic risk score (PRS) use case. Our argument is not that existing governance mechanisms are wrong but that they need an additional upstream layer. Investigators should be required to justify not only whether their models perform, but also whether their representations are truthful enough for the clinical, public health, or policy claims at hand.Keywords
All Related Versions
- Published version: Journal of Medical Internet Research, 28, e102537.
This publication has 34 references indexed in Scilit:
- Recommendations for responsible use of population descriptors in polygenic risk score developmentNature Genetics, 2025
- Community and bioethicists’ perspectives on iPSC research with biobanked samples collected using broad consentStem Cell Reports, 2025
- Sociodemographic bias in clinical machine learning models: a scoping review of algorithmic bias instances and mechanismsJournal of Clinical Epidemiology, 2024
- Guiding Principles to Address the Impact of Algorithm Bias on Racial and Ethnic Disparities in Health and Health CareJAMA Network Open, 2023
- Algorithmic Fairness and the Situated Dynamics of JusticeCanadian Journal of Philosophy, 2021
- Do no harm: a roadmap for responsible machine learning for health careNature Medicine, 2019
- Holistic prediction of enantioselectivity in asymmetric catalysisNature, 2019
- Clinical use of current polygenic risk scores may exacerbate health disparitiesNature Genetics, 2019
- A Highly Selective and Potent PTP-MEG2 Inhibitor with Therapeutic Potential for Type 2 DiabetesJournal of the American Chemical Society, 2012
- EFFECTS OF TRANSFER FACTOR IN WALDENSTROM'S MACROGLOBULINEMIA AND MULTIPLE MYELOMA**This work was supported by ACS Institutional Research Grant; Research Grant NIH CA 14395 Comprehensive Cancer Center for the State of Florida, University of Miami; Ann Pollard Research Fund; Research Grant AI-12475-NIH, National Institute Infectious & Allergic Diseases.1976